# US Ureteral Obstruction Market

> United States Ureteral Obstruction Market Research Report By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) By Material (Metallic, Silicone, Polymeric, Biodegradable) By Indication (Calculi, Tumors, Congenital Ureteral Obstructions, Inflammatory Strictures) By Product Type (Ureteral Stents, Ureteral Catheters, Balloon Dilators, Nephrostomy Tubes, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.58%
- **2024:** $ 303.8 Million
- **2025:** $ 323.79 Million
- **2035:** $ 612.38 Million
- **Key Players:** Boston Scientific (US), Medtronic (US), B. Braun Melsungen AG (DE), Cook Medical (US), Teleflex (US), Coloplast (DK), Stryker (US), Johnson & Johnson (US)

**Report ID:** MRFR/Pharma/18524-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-ureteral-obstruction-market-20071

---

## Market Summary

## US Ureteral Obstruction Market Highlighted Trends & Dynamics

In the US, the number of people with this problem affects the need for treatments that are meant to clear up ureteral blockage. Kidney stones, tumors, or problems or abnormalities present at birth are just some of the things that can lead to ureteral block. This makes it even more important for doctors to treat the illnesses that are making the block happen.

This is because the market for medicines for ureteral blockage is very busy. Because the signs were so bad and because they could hurt the kidneys, this was done. People who are in pain, have urinary tract infections, or have kidney damage from a blocked bladder should see a doctor right away to make sure their symptoms get better and their kidneys keep working right.

Recent advances in imaging and treatment have made it possible to find narrowing of the ureter earlier. For doctors to choose the best treatment, they need to know exactly where and what kind of block there is.

Ureteroscopy, laser lithotripsy, and other similar tools have made it possible for ureteral stenosis therapy to change a great deal. Patients choose less invasive surgeries that help them heal faster and with less pain. These things have an effect on the treatment they pick.

Surgery to remove the obstruction may be done in many ways. There are several options for patients, from open to laparoscopic or robotic-assisted surgeries.

Ureteral obstruction may be caused by kidney stones, tumors, or scarring, making therapy harder. Specific causes and linked problems determine treatment needs.

Patients who understand ureteral obstruction symptoms are more inclined to seek medical care. Educational initiatives that emphasize early engagement and treatment options raise the demand for urgent medical care.

US residents are living longer, increasing the demand for ureteral obstruction treatments. Kidney-blocking disorders increase with age. This suggests this group needs extra medical care.

How accessible urologists and other medical professionals are affects ureteral obstruction treatment demand. If there are enough doctors and specialist facilities, people can access fast, skilled treatment, changing the market.

Depending on insurance coverage and cost, ureteral obstruction treatments are very popular. Ureteral blockage therapies are more likely to be covered by comprehensive insurance, which affects the market.

## Market Drivers

### Increasing Prevalence of Kidney Stones

The rising incidence of kidney stones in the US is a primary driver for the ureteral obstruction market. Studies indicate that approximately 10% of the population will experience a kidney stone at some point in their lives. This condition often leads to ureteral obstruction, necessitating medical intervention. The ureteral obstruction market is likely to benefit from this trend, as healthcare providers seek effective solutions to manage and treat these obstructions. Furthermore, the economic burden associated with kidney stones, estimated at over $5 billion annually in the US, underscores the need for innovative treatment options. As awareness of kidney stone prevention and management grows, the demand for ureteral obstruction treatments is expected to increase, further propelling market growth.

### Advancements in Minimally Invasive Procedures

The ureteral obstruction market is experiencing a shift towards minimally invasive surgical techniques. These advancements, including ureteroscopy and laser lithotripsy, offer patients reduced recovery times and lower complication rates compared to traditional surgical methods. The adoption of these technologies is likely to enhance patient outcomes and satisfaction, driving demand for ureteral obstruction treatments. According to recent data, minimally invasive procedures have shown a success rate of over 90% in treating ureteral obstructions, which may encourage more healthcare facilities to invest in these technologies. As the healthcare landscape continues to evolve, the emphasis on patient-centered care and efficient treatment options will likely sustain the growth of the ureteral obstruction market.

### Aging Population and Associated Health Issues

The demographic shift towards an aging population in the US is a significant factor influencing the ureteral obstruction market. As individuals age, the likelihood of developing urinary tract disorders, including ureteral obstructions, increases. The US Census Bureau projects that by 2030, nearly 20% of the population will be 65 years or older. This demographic trend suggests a growing need for effective management of ureteral obstructions, thereby expanding the market. Additionally, older adults often have comorbidities that complicate urinary health, further driving the demand for specialized treatments. The ureteral obstruction market must adapt to these changing demographics to meet the needs of this population segment.

### Technological Integration in Healthcare Systems

The integration of advanced technologies within healthcare systems is poised to impact the ureteral obstruction market positively. Innovations such as telemedicine, electronic health records, and artificial intelligence are streamlining patient care and improving treatment outcomes. These technologies facilitate better diagnosis and management of ureteral obstructions, potentially leading to increased patient engagement and adherence to treatment plans. The ureteral obstruction market may see a rise in demand as healthcare providers leverage these technologies to enhance service delivery. Moreover, the potential for data analytics to identify trends in patient outcomes could inform future treatment protocols, further driving market growth.

### Rising Awareness and Education on Urological Health

Increased awareness and education regarding urological health are contributing to the growth of the ureteral obstruction market. Public health campaigns and educational initiatives have highlighted the importance of early detection and treatment of urinary disorders. This heightened awareness is likely to lead to more individuals seeking medical advice for symptoms related to ureteral obstruction. As patients become more informed about their health, they may be more inclined to pursue treatment options, thereby driving market demand. Furthermore, healthcare providers are increasingly focusing on patient education as part of their practice, which may further enhance the visibility of ureteral obstruction treatments within the healthcare system.

## Future Outlook

The [Ureteral Obstruction Market](https://www.marketresearchfuture.com/reports/ureteral-obstruction-market-4041) is projected to grow at a 6.58% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of urinary disorders, and enhanced healthcare access.

**New opportunities:**

- Development of minimally invasive surgical devices for outpatient procedures. Expansion of telehealth services for remote patient monitoring and consultations. Investment in AI-driven diagnostic tools to improve early detection and treatment planning.

By 2035, the ureteral obstruction market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Product Type: Ureteral Stents (Largest) vs. Balloon Dilators (Fastest-Growing)

In the US ureteral obstruction market, the product types exhibit varying market shares with ureteral stents leading due to their wide application and established demand in clinical settings. Ureteral catheters and nephrostomy tubes also hold significant shares, though less than stents, while others like balloon dilators make up a smaller segment of the market. This diverse distribution reflects the different clinical perceptions and usage patterns that exist across the treatment spectrum.

Growth trends reveal that balloon dilators are currently the fastest-growing segment, attributed to advances in technology and increased awareness regarding minimally invasive procedures. The demand for effective solutions for ureteral obstruction is driving innovation, as healthcare providers seek alternatives to traditional methods. The aging population and an increase in urinary tract disorders are key factors propelling this market forward, particularly for balloon dilators which offer compelling benefits such as enhanced patient comfort and recovery time.

Ureteral Stents (Dominant) vs. Balloon Dilators (Emerging)

Ureteral stents remain the dominant product type in the US ureteral obstruction market, primarily due to their essential role in managing urinary obstructions and their proven effectiveness. These stents are widely used in various clinical scenarios, promoting their popularity and sustained demand. In contrast, balloon dilators are emerging as an innovative solution, resonating with healthcare providers looking for less invasive options. Balloon dilators facilitate the dilation of strictures or blockages efficiently and are becoming preferred due to their ability to minimize patient discomfort and improve procedural outcomes. The competition between these segments highlights a shift towards more sophisticated, patient-friendly solutions in urological care.

### By End-user: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the US ureteral obstruction market, hospitals represent the largest end-user segment, capturing a significant portion of the market share due to their comprehensive infrastructure and resources for handling complex cases. Ambulatory Surgical Centers (ASCs) follow closely, providing a growing alternative for less complicated procedures, which is appealing to both patients and healthcare providers interested in efficiency and cost-effectiveness.

The growth trends in this segment are influenced by several factors, including an increasing prevalence of ureteral obstruction cases, advancements in minimally invasive surgical techniques, and a shift towards outpatient care. The rising number of ASCs is particularly notable as they offer a quicker, more convenient option for patients, thus driving their rapid expansion and attraction. Hospitals maintain their dominance through a broader service range and higher patient volume, but ASCs are emerging as a vital player fueled by changing patient preferences.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals dominate the US ureteral obstruction market due to their ability to provide comprehensive care, including advanced diagnostic tools and treatment options, which cater to a wide range of patient needs. They are equipped with skilled professionals and have the capacity to handle complex surgical cases effectively. On the other hand, Ambulatory Surgical Centers are emerging as a viable alternative for patients requiring less invasive procedures. These centers are designed for efficiency and patient comfort, often leading to quicker recovery times. As outpatient care continues to gain traction, ASCs are positioned to capitalize on this trend, making them a growing competitor to traditional hospital services.

### By Indication: Calculi (Largest) vs. Tumors (Fastest-Growing)

The market share distribution among the indication segment values highlights Calculi as the leading contributor, primarily due to a high incidence rate of kidney stones in the population. Tumors follow as a significant, though slightly smaller segment, while Congenital Ureteral Obstructions and Inflammatory Strictures represent emerging areas of interest. The steady growth of the segment values indicates a concentrated focus on the prevailing health challenges in the region. 

As we analyze growth trends, Tumors exhibit rapid expansion, reflecting advancements in diagnostic technologies and increasing awareness around urinary tract-related cancer. On the other hand, Calculi remains consistently strong, bolstered by rising obesity rates and lifestyle factors contributing to kidney stone formations. The push for minimally invasive treatment options further enhances the adoption rates of solutions within these indications.

Calculi (Dominant) vs. Tumors (Emerging)

The Calculi indication leads the US ureteral obstruction market, characterized by a dominant presence due to prevalent conditions associated with kidney stones. Patients suffering from Calculi require urgent solutions, resulting in a vibrant market for treatments and interventions. On the other hand, the Tumors indication is emerging rapidly, driven by increasing diagnosis rates of urinary tract tumors and a growing focus on cancer treatment innovations. Although Tumors currently capture a smaller market share compared to Calculi, the rapid advancements in medical technology and rising patient awareness are expected to fuel significant growth. Both segments illustrate a clear divergence in their clinical focus and treatment strategies, underscoring their respective market roles.

### By Material: Metallic (Largest) vs. Silicone (Fastest-Growing)

The market for materials used in the US ureteral obstruction market shows a distinct distribution among various segment values. Metallic materials currently hold the largest share due to their robustness and long-standing use in medical applications. Silicone, while comparatively smaller in market share, is gaining traction thanks to its biocompatibility and flexibility, creating a dynamic landscape in which innovation is paramount.

Growth trends indicate a rising preference for silicone due to its advantages in patient comfort and reduced tissue irritation. Additionally, the increasing acceptance of biodegradable materials in the market signifies a pivotal shift driven by sustainability trends. As healthcare professionals seek improved options for patient care, the demand for silicone is projected to surge, marking it as a fast-growing segment within this market.

Metallic: Dominant vs. Silicone: Emerging

Metallic materials dominate the landscape in the US ureteral obstruction market, recognized for their durability, resistance to deformation, and ability to be sterilized multiple times without degradation. This long-established segment benefits from a wide array of applications ranging from stents to guidewires, fostering trust among healthcare professionals. Conversely, silicone is emerging as a significant alternative, appreciated for its flexible properties and reduced risk of internal injuries. As clinicians become increasingly aware of patient comfort and the long-term implications of material choice, silicone's market presence is anticipated to rise, potentially challenging the dominance of metallic materials in the near future.

## Competitive Benchmarking

The ureteral obstruction market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Boston Scientific (US), Medtronic (US), and Teleflex (US) are actively pursuing strategies that emphasize technological advancements and operational efficiencies. Boston Scientific (US) has positioned itself as a leader in minimally invasive solutions, while Medtronic (US) focuses on integrating digital health technologies into its product offerings. Teleflex (US), on the other hand, is enhancing its portfolio through strategic acquisitions, thereby broadening its market reach and capabilities. Collectively, these strategies contribute to a dynamic competitive environment where companies are not only vying for market share but also striving to improve patient outcomes through innovative solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the ureteral obstruction market appears moderately fragmented, with several players holding significant shares. This fragmentation allows for a diverse range of products and solutions, fostering competition that drives innovation. The influence of key players is substantial, as their strategic initiatives often set industry standards and trends.

In October  Medtronic (US) announced the launch of its new digital health platform aimed at improving patient monitoring and engagement in ureteral obstruction treatments. This strategic move is likely to enhance patient outcomes by providing real-time data to healthcare providers, thereby facilitating timely interventions. The integration of digital health solutions into traditional treatment paradigms signifies a shift towards more personalized and effective care.

In September  Boston Scientific (US) expanded its product line with the introduction of a novel ureteral stent designed to reduce complications associated with traditional stenting methods. This innovation not only reinforces Boston Scientific's commitment to improving patient safety but also positions the company to capture a larger market share by addressing unmet clinical needs. The emphasis on product innovation is indicative of the company's strategy to differentiate itself in a competitive market.

In August  Teleflex (US) completed the acquisition of a leading manufacturer of ureteral access sheaths, thereby enhancing its product portfolio and market presence. This acquisition is strategically significant as it allows Teleflex to offer a more comprehensive range of solutions for ureteral obstruction, potentially increasing its competitive edge. The consolidation of resources and expertise through such acquisitions is likely to drive further innovation and efficiency in product development.

As of November  current trends in the ureteral obstruction market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances innovation and accelerates product development. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards a focus on technological innovation, supply chain reliability, and enhanced patient care solutions. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive advantage.

## Report Scope

| MARKET SIZE 2024 | 303.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 323.79(USD Million) |
| MARKET SIZE 2035 | 612.38(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.58% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Boston Scientific (US), Medtronic (US), B. Braun Melsungen AG (DE), Cook Medical (US), Teleflex (US), Coloplast (DK), Stryker (US), Johnson & Johnson (US) |
| Segments Covered | Product Type, End-user, Indication, Material |
| Key Market Opportunities | Advancements in minimally invasive surgical techniques enhance treatment options in the ureteral obstruction market. |
| Key Market Dynamics | Technological advancements in ureteral obstruction treatments drive competitive dynamics and regulatory adaptations in the market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US ureteral obstruction market in 2024?**
A: The market valuation was $303.8 Million in 2024.

**Q: What is the projected market valuation for the US ureteral obstruction market by 2035?**
A: The projected valuation for 2035 is $612.38 Million.

**Q: What is the expected CAGR for the US ureteral obstruction market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.58% during the forecast period 2025 - 2035.

**Q: Which product type generated the highest revenue in the US ureteral obstruction market in 2024?**
A: Ureteral Stents generated the highest revenue, with a valuation between $100.0 Million and $200.0 Million.

**Q: What are the key end-user segments in the US ureteral obstruction market?**
A: Key end-user segments include Hospitals, Ambulatory Surgical Centers, and Specialty Clinics.

**Q: What was the revenue range for ureteral catheters in 2024?**
A: The revenue range for ureteral catheters was between $70.0 Million and $140.0 Million.

**Q: Which indication accounted for the highest revenue in the US ureteral obstruction market in 2024?**
A: Calculi accounted for the highest revenue, with a valuation between $121.52 Million and $246.12 Million.

**Q: What materials are used in ureteral stents within the US market?**
A: Materials used include Metallic, Silicone, Polymeric, and Biodegradable.

**Q: What is the revenue range for specialty clinics as an end-user in 2024?**
A: The revenue range for specialty clinics was between $91.14 Million and $182.14 Million.

**Q: Which company is a key player in the US ureteral obstruction market?**
A: Boston Scientific is one of the key players in the US ureteral obstruction market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-ureteral-obstruction-market-20071*